Moleculin Biotech, Inc. Noncash or Part Noncash Acquisition, Payables Assumed
Moleculin Biotech, Inc. (MBRX) reported Noncash or Part Noncash Acquisition, Payables Assumed of $0 for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-11.
Discontinued › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1 · last filed 2017-08-11
- 2017-06-30: Noncash or Part Noncash Acquisition, Payables Assumed 6 month $0.00.
- 2016-06-30: Noncash or Part Noncash Acquisition, Payables Assumed 6 month $100.00K.
| Period end | Noncash or Part Noncash Acquisition, Payables Assumed 6 month |
|---|---|
| 2017-06-30 | $0.00 10-Q · filed 2017-08-11 |
| 2016-06-30 | $100.00K 10-Q · filed 2017-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |